Natera, Inc. (NTRA) Analyst Ratings & Price Targets

Natera, Inc.

NTRA · Nasdaq

Analyst Consensus

Buy

14 analysts

$342

Current

—

Low

$350

Average

—

High

Average target implies +2.34% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy from 14 analysts, with a mean price target of $295. The supplied data provide no low or high target, so target clustering and the width of the range cannot be established; they also do not identify the most or least bullish analyst. No analyst-rating or target revisions are reported for the past week, and no firm-specific disagreement is documented. The available substantive backdrop is therefore limited: the stock closed at $275.19 versus the mean target, while Natera’s revenue rose from $1.7 billion in FY2024 to $2.3 billion in FY2025 but net income remained negative at roughly $0.2 billion in both years.

Rating Actions

No individual rating actions have been captured for NTRAyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?The Motley Fool
Uncertain

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

BAIRD R W

BTIG

GOLDMAN SACHS

GUGGENHEIM SEC.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

PIPER SANDLER

RAYMOND JAMES

SANFORD BERNSTE

STEPHENS INC

TD COWEN

UBS

WOLFE RESEARCH

Symbol: NTRA
Type: Stock
Sector: Health Care
Industry: Services-Medical Laboratories
Exchange: Nasdaq

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas , and San Carlos, California , and through Foresight Diagnostics , its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Key Issues

Bullish view

The PMDA filing could broaden Signatera’s addressable market by enabling companion-diagnostic use in Japanese muscle-invasive bladder cancer.

Bearish view

The filing is only an application, not an approval, and the evidence gives no timetable, commercial terms, or expected revenue contribution.

Analyst Consensus

See all

Buy

14 analysts

$342

Current

—

Low

$350

Average

—

High

Average target implies +2.34% versus the current price.

Earnings History

BeatMissNo estimate

Natera, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers